Study S000245

A Phase 1, Open-label, Randomized, Parallel Group Study to Assess the Relative Bioavailability of Two Maridebart Cafraglutide (AMG 133) Drug Products in Participants Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07832799
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 340
Start: 2026-10-12
Primary completion: 2027-03-23
Lead sponsor: Amgen
Conditions: Overweight; Obesity
Interventions: DRUG:Maridebart Cafraglutide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Area Under the Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) of Maridebart Cafraglutide [Up to Day 120]
Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Maridebart Cafraglutide [Up to Day 120]
Maximum Observed Concentration (Cmax) of Maridebart Cafraglutide [Up to Day 120]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.